Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H21NO.ClH |
Molecular Weight | 291.816 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2
InChI
InChIKey=LUCXVPAZUDVVBT-UNTBIKODSA-N
InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1
Molecular Formula | C17H21NO |
Molecular Weight | 255.3547 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | ( - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/atomoxetine.html
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/atomoxetine.html
Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter. Most common adverse reactions are: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence, constipation, dry mouth, dizziness, erectile dysfunction, and urinary hesitation. Atomoxetine is a substrate for CYP2D6 and hence concurrent treatment with CYP2D6 inhibitors such as bupropion (Wellbutrin) or fluoxetine (Prozac) is not recommended, as this can lead to significant elevations of plasma atomoxetine levels.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800000561
Curator's Comment: # Eli Lilly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
5.0 nM [Ki] | |||
Target ID: CHEMBL228 |
77.0 nM [Ki] | ||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12431845 |
1451.0 nM [Ki] | ||
Target ID: Q00959 Gene ID: 24409.0 Gene Symbol: Grin2a Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20423340 |
1.58 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | STRATTERA Approved UseAttention-Deficit/Hyperactivity Disorder (ADHD) STRATTERA is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of STRATTERA Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see Clinical Studies (14) Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
414.82 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ATOMOXETINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2693.29 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ATOMOXETINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23812961 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
ATOMOXETINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
ATOMOXETINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Drug development process for a product with a primary pediatric indication. | 2002 |
|
Drugs under investigation for attention-deficit hyperactivity disorder. | 2002 Aug |
|
Castration increases nisoxetine-evoked norepinephrine levels in vivo within the olfactory bulb of male rats. | 2002 Aug 9 |
|
Gateways to clinical trials. | 2002 Dec |
|
Gateways to clinical trials. | 2002 Nov |
|
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. | 2002 Nov |
|
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. | 2002 Nov |
|
Cardiovascular effects of atomoxetine in children, adolescents, and adults. | 2003 |
|
Atomoxetine. | 2003 |
|
Pharmacological treatments for ADHD and the novel agent atomoxetine. | 2003 Aug |
|
Atomoxetine and pregnancy. | 2003 Aug |
|
Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. | 2003 Jan |
|
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. | 2003 Jan 15 |
|
Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. | 2003 Jul |
|
Gateways to clinical trials. | 2003 May |
|
Atomoxetine for attention deficit/hyperactivity disorder. | 2003 May |
|
The use of antidepressants to treat attention deficit hyperactivity disorder in adults. | 2003 Sep |
|
Enhanced attention in rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential. | 2003 Sep |
|
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. | 2003 Spring |
|
Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. | 2004 |
|
Impact of ADHD and its treatment on substance abuse in adults. | 2004 |
|
ADHD treatment across the life cycle. | 2004 |
|
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. | 2004 Aug |
|
Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. | 2004 Aug |
|
[Tourette syndrome: an analysis of its comorbidity and specific treatment]. | 2004 Feb |
|
[New therapeutic options in the treatment of attention deficit/hyperactivity disorder]. | 2004 Feb |
|
New drugs 04, part 1. | 2004 Feb |
|
Gateways to clinical trials. | 2004 Jan-Feb |
|
The use of atomoxetine adjunctively in fibromyalgia syndrome. | 2004 Jul |
|
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. | 2004 Jul |
|
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. | 2004 Jul |
|
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. | 2004 Jun |
|
Acute oxcarbazepine and atomoxetine overdose with quetiapine. | 2004 Jun |
|
Pharmacological management of attention-deficit hyperactivity disorder. | 2004 Jun |
|
Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. | 2004 Jun |
|
Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. | 2004 Jun |
|
New drugs of 2003. | 2004 Mar-Apr |
|
[Attention-deficit/hyperactivity disorder (ADHS) in adulthood]. | 2004 Mar-Apr |
|
Atomoxetine hydrochloride. | 2004 May |
|
Potential noradrenergic targets for cognitive enhancement in schizophrenia. | 2004 May |
|
Adrenergic alpha 2C receptor genomic organization: association study in adult ADHD. | 2004 May 15 |
|
New drugs for the treatment of attention-deficit/hyperactivity disorder. | 2004 Nov |
|
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. | 2004 Nov |
|
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. | 2004 Nov 15 |
|
A lifetime of distractions. ADHD is no longer just a children's disease. Many adults are being diagnosed and treated for the condition. | 2004 Oct |
|
[Atomoxetine for the treatment of attention-deficit/hyperactivity disorder]. | 2004 Oct |
|
Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. | 2004 Sep |
|
Gateways to clinical trials. | 2004 Sep |
|
Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. | 2004 Spring |
|
Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. | 2005 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/atomoxetine.html
Atomoxetine should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20423340
Electrophysiological recordings was performed with the extracellular standard solution at different membrane potentials ranging from -80 mV to +40 mV while the concentration of the agonists (100 uM NMDA/10 uM glycine) and the antagonist (25 uM atomoxetine) were kept constant. The inhibitory effect was clearly voltage-dependent, so that the inhibition was attenuated by depolarization.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:36:36 GMT 2025
by
admin
on
Mon Mar 31 17:36:36 GMT 2025
|
Record UNII |
57WVB6I2W0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
173003
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57WVB6I2W0
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
353103
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | RxNorm | ||
|
331697
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
82248-59-7
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
C47405
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
SUB75495
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
m2124
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
759104
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL641
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
57WVB6I2W0
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
DTXSID2044266
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
DB00289
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
1044469
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
100000137397
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
T-123
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY | |||
|
54840
Created by
admin on Mon Mar 31 17:36:36 GMT 2025 , Edited by admin on Mon Mar 31 17:36:36 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ENANTIOMER -> ENANTIOMER |
|
||
|
RACEMATE -> ENANTIOMER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|